At AGA Nanotech, scientific innovation and collaboration are at the core of our mission to combat antimicrobial resistance (AMR). Through partnerships with leading global institutions, we have developed cutting-edge, non-antibiotic antimicrobial solutions validated by peer-reviewed research.
Our research underscores our commitment to delivering sustainable solutions that advance both human and animal health.
The study demonstrates a novel approach to deliver hydrogen peroxide (H₂O₂) and peracetic acid (PAA) using biodegradable microparticles. The use of Thermally Induced Phase Separation (TIPS) to manufacture these microparticles avoids premature compound decomposition, ensuring controlled and sustained antimicrobial activity.
The microparticles were highly effective against multidrug-resistant organisms such as methicillin-resistant Staphylococcus aureus (MRSA) and carbapenem-resistant Escherichia coli (CREC). The controlled release of oxidative biocides ensured sustained bacterial killing without associated cytotoxicity in vitro or adverse reactions in vivo.
One of the biggest challenges in antimicrobial technology is balancing efficacy with safety. This study proves that Battlestar technology achieves effective bacterial eradication while minimizing host tissue damage, a major advancement over conventional biocides.
The Battlestar technology does not promote the development of bacterial resistance, making it a promising alternative to traditional antibiotics in clinical applications.
Read the full paper hereThe study explores a novel approach where cold plasma is used to activate acetyl donor molecules (TAED and PAG) for generating reactive oxygen and nitrogen species (RONS). This process produces a potent antimicrobial formulation that includes hydrogen peroxide (H₂O₂) and peracetic acid (PAA), both highly effective against resistant pathogens.
The cold plasma-activated solution demonstrated exceptional efficacy in eradicating Pseudomonas aeruginosa and Staphylococcus aureus, two bacteria commonly found in chronic wound infections. In addition to bacterial decontamination, the solution reduced SARS-CoV-2 viral load by over 84%, highlighting its potential in viral decontamination.
The formulation can be used in various formats, such as gels, creams, or wound dressings, and can be activated on-demand using cold plasma. This technology has the potential for wide applications in healthcare, including disinfecting hospital surfaces and treating infections in a more sustainable, antibiotic-free manner.
With the growing threat of AMR, this study provides a critical step toward developing non-antibiotic solutions for microbial eradication. The synergistic action of RONS and the on-demand generation of biocides like PAA offers a promising alternative to traditional antibiotics without contributing to resistance.
Read the full paper hereThis study investigates the plasma-activated solutions of TAED and PAG and their ability to enhance the production of reactive oxygen and nitrogen species (RONS), including hydrogen peroxide (H₂O₂) and peracetic acid (PAA). Plasma activation significantly increases the antibacterial efficacy of these solutions.
Plasma-activated TAED and PAG both exhibited strong bactericidal activity against Pseudomonas aeruginosa and Staphylococcus aureus. PAG was found to be more effective at generating PAA, contributing to its stronger antibacterial properties compared to TAED, which produced more H₂O₂.
The study highlighted that PAG’s higher production of PAA makes it more resistant to bacterial catalase, an enzyme that neutralizes H₂O₂. This enhances the potential for using PAG in plasma-activated solutions for antimicrobial applications.
This plasma-activated technology shows promise in a wide range of healthcare and industrial settings, including wound care, infection control, and food safety, offering a potent, non-antibiotic solution to combat AMR.
Read the full paper hereThe study tested encapsulated peracetic acid (PAA) in broiler chickens and found it to be an effective broad-spectrum antimicrobial alternative. Two concentrations of PAA (30 mg/kg and 80 mg/kg) were tested, showing improved growth performance, reduced bacterial load, and beneficial shifts in the gut microbiota without harmful by-products.
Birds fed 30 mg/kg of PAA showed decreased Firmicutes and increased Proteobacteria in the jejunum. This was accompanied by an increase in beneficial genera such as Bacillus and Flavonifractor in the caeca, promoting better gut health and reduced abundance of tetracycline resistance genes.
Broiler chickens fed with encapsulated PAA exhibited improved body weight gain and feed conversion ratios, particularly at the lower concentration of 30 mg/kg. The results suggest that PAA, delivered via hydrolysis of encapsulated precursors, supports better animal performance while mitigating the risk of antimicrobial resistance.
The study observed a significant reduction in antimicrobial resistance (AMR) gene abundance, particularly tetracycline resistance genes, in birds treated with PAA. This highlights the potential of PAA to address the AMR challenge in livestock farming.
The findings suggest that reusing poultry litter in combination with PAA treatment could improve animal performance and reduce the spread of AMR. This has important implications for sustainable livestock farming and global food security.
Read the full paper hereThis study assesses the use of in-water PAA derived from precursors sodium percarbonate (SP) and tetraacetylethylenediamine (TAED) as an alternative to antibiotics for controlling pathogens in broiler chickens. Administered at concentrations ranging from 10 to 50 ppm, PAA demonstrated improvements in growth performance and bacterial load reduction.
Broiler chickens treated with PAA at 20, 30, and 40 ppm exhibited a significant increase in body weight by day 14 compared to control birds, showing improvements of up to 12.5%. Feed intake was also enhanced, with PAA-treated birds consuming more feed during the experimental period.
PAA treatment led to a reduction in bacterial concentration in the crop, particularly at 20 and 50 ppm levels. The study also revealed changes in gut microbiota, including a decrease in Lactobacillus and an increase in beneficial gut bacteria, which contributed to improved performance and overall health.
The study analysed six antimicrobial resistance (AMR) genes and found that PAA treatments, especially at higher concentrations, showed a reduction in certain AMR genes. This highlights the potential of PAA as a tool to combat the spread of AMR in poultry farming.
By reducing the bacterial load and supporting better gut health without the use of traditional antibiotics, PAA offers a sustainable alternative for enhancing poultry performance and food security while mitigating the risk of AMR.
Read the full paper here